Dergiler / Neurological sciences and neurophysiology (Online) / 2019 / Cilt: 36 - Sayı: 3

Examination of IL-1β level as an inflammasome marker in Alzheimer's disease

Sayfa
141–147
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This result may indicate that stronger relations will be determined in large-scale studies involving larger numbers of patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Interleukin (IL)-1β is believed to be responsible for the neurotoxicity of amyloid plaques in Alzheimer’s disease (AD).
📊
Temel Bulgular & Veri:In the present study, serum levels of IL-1β, and correlations with clinical features and neuropsychiatric test results were examined.Methods: Thirty-eight patients with AD and 38 healthy control patients were included in the study.
💡
Sonuç & Katkı:This result may indicate that stronger relations will be determined in large-scale studies involving larger numbers of patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Interleukin (IL)-1β is believed to be responsible for the neurotoxicity of amyloid plaques in Alzheimer’s disease (AD). In the present study, serum levels of IL-1β, and correlations with clinical features and neuropsychiatric test results were examined.Methods: Thirty-eight patients with AD and 38 healthy control patients were included in the study. Serum IL-1β levels in pa-tients with AD and control were analyzed using enzyme-linked immunosorbent assay method. The Mini-Mental Test Score (MMSE) and Geriatric Depression Scale (GDS) were administered to both the patient and control groups. Furthermore, the clin-ical dementia rating, detailed neuropsychological test battery, and neuropsychiatric inventory were administered to the AD group. It was determined that the serum IL-1β measurements of the patient and control groups were not statistically different, and IL-1β measurements in the patient group were not correlated with the MMSE and GDS.Results: The relationship of IL-1β measurements in the patient group with other clinical data was not significant. Among the patients' neuropsychological tests, a moderately, significant negative correlation was found only between the clock drawing test and visual learning score and serum IL-1β levels.Conclusion: Our study is in agreement with other studies in which no significant difference was found between patients with AD and healthy controls in terms of serum IL-1β levels, but the moderately negative correlation obtained with the clock drawing test and visual learning score indicates a weak relation. This result may indicate that stronger relations will be determined in large-scale studies involving larger numbers of patients.

🔖

Bu Makaleye Atıf Yap

TANBUROĞLU, A., GENÇ, Ş., EREN, E., DEMİR, N., VURGUN, U., YENER, G., BULUT, O., BÖLÜK, G. (2022). Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. Neurological sciences and neurophysiology (Online), Cilt: 36 - Sayı: 3, 141–147. https://ajindex.com/articles/584325

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56: 321-339. [CrossRef] 2. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzhei-mer's disease. Neurobiol Aging 2000; 21: 383-421. [CrossRef] 3. Wegiel J, Wang KC, Imaki H, et al. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol Aging 2001; 22: 49-61. [CrossRef] 4. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9: 857-865. [CrossRef] 5. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86: 7611-7615. [CrossRef] 6. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-3732. [CrossRef] 7. Webb AC, Collins KL, Auron PE, et al. Interleukin-1 gene (IL1) as-signed to long arm of human chromosome 2. Lymphokine Res 1986; 5: 77-85. 8. Güngen C, Ertan T, Eker E, Yaşar R, Engin F. Reliability and validi-ty of the standardized Mini Mental State Examination in the di-agnosis of mild dementia in Turkish population. Turk Psikiyatri Derg 2002; 13: 273-281. 9. Öktem Tanör Ö. Öktem Sözel Bellek Süreçleri Testi (Öktem-VMPT) El Kitabı. Türk Psikologlar Derneği Yayınları, 2011, No: 34, Ankara. 10. Wechsler D. Manual for the Wechsler Memory Scale-Revised, The Psychological Corporation, 1987,
  2. San Antonio, TX. 11. Tumaç A. The effect of age and education on performance in some frontal damage-susceptible tests in normal subjects. İs-tanbul Üniversitesi,
  3. Sosyal Bilimler Enstitüsü, Unpublished mas-ter's thesis, 1997. 12. Öktem Tanör Ö. Nöropsikolojik Değerlendirme In: Tanrıdağ O, Davranış Nörolojisi, Nobel Tıp Kitabevleri, 2016, İstanbul. 13. Shulman KI, Gold DP, Cohen CA, Zucchero CA. Clock-drawing and dementia in the community: A longitudinal study. Int J Geri-atr Psychiatry 1993; 8: 487-496. [CrossRef] 14. Fernández-Blázquez MA, Ruiz-Sánchez de León JM, López-Pina JA, Llanero-Luque M, Montenegro-Peña M, Montejo-Carrasco P. A new shortened version of the Boston Naming Test for those aged over 65: an approach from item response theory. Rev Neu-rol 2012; 55: 399-407. [CrossRef] 15. Ertan T, Eker E. Reliability, validity, and factor structure of the geriatric depression scale in Turkish elderly: are there different factor structures for different cultures? Int Psychogeri